

7TH INTERNATIONAL VETERINARY CONGRESS

September 04-05, 2017 | Paris, France

Comparative purity of various canine *Leptospira* vaccines based on the concentration in bovine serum albumin

Christelle Fontaine, Denis Blond, Sandrine Fournel and Ariane Van De Moer
VIRBAC, France

Introduction: Bovine serum albumin (BSA), one component of culture media frequently used for vaccines manufacturing can be one of the allergens responsible for immediate-type allergic reactions post vaccination in dogs. Allergic reactions are the major pharmacovigilance reported signs in dogs given *Leptospira* vaccines. The study aim was to compare the quantity of BSA in various dog *Leptospira* vaccines.

Methodology: Four commercial vaccines from different manufacturers were used. The vaccines tested contained two (Canigen™ L, Virbac), three (Vaccine B) or four (Vaccine D and E) serovars of *Leptospira*. The concentration in BSA in each vaccine was determined by ELISA assay (Bovine Serum Albumin Assay, Cygnus Technologies). Statistical tests were performed using the non-parametric Dunn's test, Jmp v10 software (SAS Institute). $P < 0.05$ was considered as significant.

Results: The lowest concentration in BSA was observed in Canigen™ L vaccine, with values at the low detection limit of the method used, ie 1 µg/mL. Vaccine B had a concentration in BSA above the detection threshold, i.e., 64 µg/mL. For Vaccines C and D, mean concentrations in BSA were respectively 21.9 ± 7.6 µg/mL and 6.0 ± 0.2 µg/mL. Significant differences could be observed between Canigen™ L vaccine and Vaccine B ($p = 0.01$) and between Canigen™ L vaccine and Vaccine C ($p = 0.04$).

Conclusion: The commercial vaccine containing two serovars of *Leptospira*, Canigen™ L, was the one with the lowest concentration in BSA, which is in line with the highest safety reported from the field. Interestingly, the concentration in BSA was not strictly correlated to the number of *Leptospira* serovars included in each of the vaccines, which could be explained by special filtration steps applied during the vaccines manufacturing processes. In conclusion, the vaccine containing two serovars of *Leptospira*, Canigen™ L remains globally purer than vaccines containing additional serovars of *Leptospira*, which might explain its highest safety.

Biography

Christelle Fontaine is a Medical Manager, Companion Animals, Virbac. She is involved in phase IV trials and collaboration with universities and specialists across the world. She graduated from the French Veterinary School of Maison Alfort, in Paris in 2007.

christelle.fontaine@virbac.com

Notes: